They reported that the combination of ceralasertib plus anti-programmed-cell death ligand-1 (PD-L1) antibody allowed major tumor control in subcutaneous models of CRC (mouse CT26, MC38 CRC cells) and lymphoma (A20 cells). This evidence concerns the gene CD274 and neoplasm.